These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10541377)

  • 21. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes.
    Engel P; Nojima Y; Rothstein D; Zhou LJ; Wilson GL; Kehrl JH; Tedder TF
    J Immunol; 1993 Jun; 150(11):4719-32. PubMed ID: 7684411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
    Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
    Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone.
    Illidge T; Honeychurch J; Vandersteen A; Cragg M
    Cancer Biother Radiopharm; 2000 Dec; 15(6):581-91. PubMed ID: 11190490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
    Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
    Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
    DiJoseph JF; Goad ME; Dougher MM; Boghaert ER; Kunz A; Hamann PR; Damle NK
    Clin Cancer Res; 2004 Dec; 10(24):8620-9. PubMed ID: 15623646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epratuzumab: targeting B-cell malignancies through CD22.
    Coleman M; Goldenberg DM; Siegel AB; Ketas JC; Ashe M; Fiore JM; Leonard JP
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3991S-4S. PubMed ID: 14506198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
    Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD
    Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
    Kaminski MS; Zasadny KR; Francis IR; Fenner MC; Ross CW; Milik AW; Estes J; Tuck M; Regan D; Fisher S; Glenn SD; Wahl RL
    J Clin Oncol; 1996 Jul; 14(7):1974-81. PubMed ID: 8683227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
    Bonardi MA; Bell A; French RR; Gromo G; Hamblin T; Modena D; Tutt AL; Glennie MJ
    Int J Cancer Suppl; 1992; 7():73-7. PubMed ID: 1428411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretargeted radioimmunotherapy for B-cell lymphomas.
    Green DJ; Pagel JM; Pantelias A; Hedin N; Lin Y; Wilbur DS; Gopal A; Hamlin DK; Press OW
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5598s-5603s. PubMed ID: 17875795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma.
    Vose JM; Colcher D; Gobar L; Bierman PJ; Augustine S; Tempero M; Leichner P; Lynch JC; Goldenberg D; Armitage JO
    Leuk Lymphoma; 2000 Jun; 38(1-2):91-101. PubMed ID: 10811451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
    Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
    J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
    Hindorf C; Lindén O; Tennvall J; Wingårdh K; Strand SE
    Acta Oncol; 2005; 44(6):579-88. PubMed ID: 16165917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
    Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
    J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
    Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
    Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential expression of the B cell-restricted molecule CD22 on neonatal B lymphocytes depending upon antigen stimulation.
    Viemann D; Schlenke P; Hammers HJ; Kirchner H; Kruse A
    Eur J Immunol; 2000 Feb; 30(2):550-9. PubMed ID: 10671211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1.1 monoclonal antibody.
    Badger CC; Krohn KA; Peterson AV; Shulman H; Bernstein ID
    Cancer Res; 1985 Apr; 45(4):1536-44. PubMed ID: 3978621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.
    Goldenberg DM; Horowitz JA; Sharkey RM; Hall TC; Murthy S; Goldenberg H; Lee RE; Stein R; Siegel JA; Izon DO
    J Clin Oncol; 1991 Apr; 9(4):548-64. PubMed ID: 2066752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.